(Q35194343)

7 August 2017

1 reference

title

Insulin glargine: an updated review of its use in the management of diabetes mellitus (English)

1 reference

7 August 2017

1 reference

1 reference

2

Greg L Plosker

1 reference

7 August 2017

5

Lesley J Scott

1 reference

7 August 2017

3

Gillian M Keating

1 reference

7 August 2017

4

Kate McKeage

1 reference

7 August 2017

Christopher J Dunn

1

1 reference

7 August 2017

publication date

1 January 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

63

1 reference

7 August 2017

issue

16

1 reference

7 August 2017

page(s)

1743-1778

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363160-00007

7 August 2017

exact match

0 references

1 reference

12 December 2020

Standards of medical care for patients with diabetes mellitus

1 reference

12 December 2020

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

12 December 2020

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

12 December 2020

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

1 reference

12 December 2020

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

1 reference

12 December 2020

Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine

1 reference

12 December 2020

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

1 reference

12 December 2020

Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus

1 reference

12 December 2020

Insulin analogs with improved pharmacokinetic profiles

1 reference

12 December 2020

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

1 reference

12 December 2020

Implications of the Diabetes Control and Complications Trial

1 reference

12 December 2020

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

12 December 2020

Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens

1 reference

12 December 2020

Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

12 December 2020

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin

1 reference

12 December 2020

Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

12 December 2020

Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus

1 reference

12 December 2020

Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients

1 reference

12 December 2020

Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

1 reference

12 December 2020

Not all long-acting insulins are the same

1 reference

12 December 2020

No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

1 reference

12 December 2020

Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus

1 reference

12 December 2020

Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles

1 reference

12 December 2020

Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review

1 reference

12 December 2020

Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.

1 reference

12 December 2020

The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits

1 reference

12 December 2020

A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

New insulins in the treatment of diabetes mellitus

1 reference

12 December 2020

Implications of the United kingdom prospective diabetes study

1 reference

12 December 2020

Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.

1 reference

12 December 2020

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

1 reference

12 December 2020

Insulin confusion: an observation

1 reference

12 December 2020

1 reference

12 December 2020

Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis.

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine

1 reference

12 December 2020

Recombinant DNA technology in the treatment of diabetes: insulin analogs

1 reference

12 December 2020

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

1 reference

12 December 2020

Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment

1 reference

12 December 2020

Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.

1 reference

12 December 2020

10.2165/00003495-200363160-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

7 August 2017

1009958899

0 references

1 reference